JPRN-jRCTs031180130已完成2 期
Phase II study of primary treatment by FOLFOXIRI+bevacizumab in patients with RAS mutant-type metastatic colorectal cancer - JACCRO CC-11
Sekikawa Takashi0 个研究点目标入组 64 人开始时间: 2019年2月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
Modified FOLFOXIRI plus bevacizumab regimen consisted of reduced dose of irinotecan and 5FU compared to dose of the TRIBE study. Primary endpoint of response rate was almost same as one of the TRIBE trial. The incidence of febrile neutropenia was 4.8%. Considering this, modified-FOLFOXIRI plus bevacizumab regimen is feasible and very effective regimen for Japanese patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 76age old（—）
- 性别
- All
入选标准
- •(1) Histologically confirmed colorectal cancer. (2) KRAS mutant-type, or RAS mutant-type. (3) Measurable leision by RECIST(Ver.1.1) (4) No past history of chemotherapy in the case of unresectable primary lesion/distant metastasis/lymph node metastasis.In the case of recurrence, no treatment for the first recurrence leision after operation. (5) Age; more than 20 years old, under 76 years old. (6) ECOG Performance status 0-1.The case >=71 years is PS0. (7) Life expectancy of more than 3 months. (8) Patiens have enough organ function for study treatment within 14 days before enrollment; 1) WBC>=3,000/mm3, <12,000/mm3. 2) Neu>=1,500/mm3. 3) PLT>=10.0x104/mm3. 4) Hb>=9.0g/dL. 5) Total Bilirubin<=1.5xULN. 6) AST<=2.5xULN. 7) ALT<=2.5xULN. 8) Creatinine<=1.5xULN. 9) Proteinuria<=1+. 10) PT-INR<=1.5. (9) Written informed consent.
排除标准
- •(1) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval. (2) Brain metastases. (3) Infectious disease. (4) Interstitial lung disease or pulmonary fibrosis. (5) Comorbidity or history of serious heart failure. (6) History of thromboembolic events. (7) Cerebrovascular disease. (8) History of hemoptysis/hematemesis. (9) Uncontrolled hypertension.(systolic BP>180mmHg, or diastolic BP>100mmHg) (10) Sensory alteration or paresthesia interfering with function. (11) Large quantity of pleural, abdominal or cardiac effusion. (12) Severe comorbidity (renal failure, liver failure, hypertension, etc) (13) Prior radiotherapy for primary and metastases leision. (14) Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test. (15) History of severe allergy. (16) HBs-Ag(+), or HCV-Ab(+). (17) Administration of blood products/ G-CSF, and blood transfusion within 14 days. (18) Surgical procedure or such as skin-open biopy, trauma surgery, or other more intensive surgeries within 28 days. (19) Systemaic administration of antiplatelet drug or NSAIDs. (20) Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy. (21) Active peptic ulcer. (22) History of gastrointestinal perforation within 1 year. (23) Unhealed traumatic bone fracture. (24) Uncontrolled diarrhea. (25) History of organ recipient . (26) Prior bevacizumab/Irinotecan/Oxaliplatin treatment.(Adjuvant therapy by Oxaliplatin is excluded) (27) Administration of atazanavir sulfate. (28) Jaundice. (29) Ileus or bowel obstruction. (30) Any other cases who are regarded as inadequate for study enrollment by investigators.
研究者
相似试验
进行中（未招募）
2 期
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05843188University Health Network, Toronto155
进行中（未招募）
2 期
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Advanced Biliary Tract CarcinomaAdvanced Gallbladder CarcinomaAdvanced Intrahepatic CholangiocarcinomaRecurrent Biliary Tract CarcinomaRecurrent Gallbladder CarcinomaRecurrent Intrahepatic CholangiocarcinomaStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Hilar Cholangiocarcinoma AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Distal Bile Duct Cancer AJCC v8Stage IV Gallbladder Cancer AJCC v8Stage IV Hilar Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Biliary Tract CarcinomaUnresectable Gallbladder CarcinomaUnresectable Intrahepatic CholangiocarcinomaNCT05564403National Cancer Institute (NCI)66
已完成
2 期
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01321957Martin-Luther-Universität Halle-Wittenberg250
进行中（未招募）
不适用
Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment lineEUCTR2014-004436-19-ITG.O.N.O.
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45